Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib/II ASP-1929 photoimmunotherapy in unresectable or non-curable esophageal squamous cell carcinoma
jRCT2080224666Phase 2Suspended
- Sponsor
- National Cancer Center Hospital East
- Start
- May 2019
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab sarotalocan sodium in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by National Cancer Center Hospital East. Started May 2019; status: suspended.
02
Drugs
cetuximab sarotalocan sodium
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on jRCT2080224666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224666.